OLK vs. TXG, CTKB, QTRX, VREX, LNTH, SEER, BIO.B, BIO, ENOV, and MRUS
Should you be buying Olink Holding AB (publ) stock or one of its competitors? The main competitors of Olink Holding AB (publ) include 10x Genomics (TXG), Cytek Biosciences (CTKB), Quanterix (QTRX), Varex Imaging (VREX), Lantheus (LNTH), Seer (SEER), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Enovis (ENOV), and Merus (MRUS). These companies are all part of the "medical" sector.
10x Genomics (NASDAQ:TXG) and Olink Holding AB (publ) (NASDAQ:OLK) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.
Olink Holding AB (publ) has lower revenue, but higher earnings than 10x Genomics. Olink Holding AB (publ) is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Olink Holding AB (publ) had 5 more articles in the media than 10x Genomics. MarketBeat recorded 10 mentions for Olink Holding AB (publ) and 5 mentions for 10x Genomics. Olink Holding AB (publ)'s average media sentiment score of 0.75 beat 10x Genomics' score of -0.09 indicating that 10x Genomics is being referred to more favorably in the media.
Olink Holding AB (publ) has a net margin of -19.72% compared to Olink Holding AB (publ)'s net margin of -42.20%. 10x Genomics' return on equity of -7.00% beat Olink Holding AB (publ)'s return on equity.
10x Genomics presently has a consensus price target of $48.50, suggesting a potential upside of 84.55%. Olink Holding AB (publ) has a consensus price target of $26.00, suggesting a potential upside of 8.29%. Given Olink Holding AB (publ)'s stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Olink Holding AB (publ).
10x Genomics received 29 more outperform votes than Olink Holding AB (publ) when rated by MarketBeat users. Likewise, 52.56% of users gave 10x Genomics an outperform vote while only 34.29% of users gave Olink Holding AB (publ) an outperform vote.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 30.2% of Olink Holding AB (publ) shares are owned by institutional investors. 10.7% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
10x Genomics has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Olink Holding AB (publ) has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
Summary
10x Genomics beats Olink Holding AB (publ) on 11 of the 18 factors compared between the two stocks.
Get Olink Holding AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olink Holding AB (publ) Competitors List
Related Companies and Tools
